Lyra Therapeutics (LYRA) Misses Q3 EPS by 12c

Lyra Therapeutics (NASDAQ: LYRA) reported Q3 EPS of ($0.85), $0.12 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $14 thousand versus the consensus estimate of $400 thousand.

Cash and cash equivalents as of September 30, 2021 were $58.1 million, compared with $69.0 million at June 30, 2021. The Company expects its cash balance to be sufficient to fund its planned operations through 2022.

For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Reading (RDI) Tops Q2 EPS by 4c